Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

This post hoc analysis of the SURMOUNT-1 study, at three years, aimed to assess weight regain from nadir weight over three years (36 months / 176 weeks) with tirzepatide treatment.

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 di ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for weight loss in a head-to-head trial with semaglutide (Ozempic, Wegovy).

The study found a significant increase in energy expenditure after four days of tirzepatide treatment, which remained elevated throughout the second week before gradually returning to control levels.

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

Health These Mini-Pigs Just Grew Human-Like Teeth—Here’s Why It Matters Biological tooth substitutes could provide better alternatives to dentures and titanium implants.

Discover how the tirzepatide weight loss study revealed boosted fat oxidation, appetite reduction, and key findings on metabolic adaptation resistance.

Eli Lilly and Company (NYSE: LLY) announced today positive topline results from the SUMMIT phase 3 clinical trial evaluating the safety and efficacy of tirzepatide injection (5 mg, 10 mg or 15 mg ...

Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial ...

Drug manufacturer Eli Lilly announced the results from a three-year study that found its drug tirzepatide slashed the risk of developing type 2 diabetes by 94% in adults with prediabetes who also ...

The study, which involved more than 1,000 prediabetic patients, found that those taking the highest dose of 15 mg lost 23% of their body weight, while those on a placebo lost just 2%. Tirzepatide is ...